Clinical Trial: Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07414979) titled 'Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma' on Feb. 13.

Brief Summary: The proposed study is a single arm Phase I trial aimed at treating up to 6 HLA-A*0201+ and HLA-A*24 02+ individuals with leptomeningeal disease from metastatic melanoma.

Study Start Date: Aug. 31, 2026

Study Type: INTERVENTIONAL

Condition: Leptomeningeal Melanoma

Intervention: DRUG: CD8+T cells

Given by infusion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Disclaimer: Curated by HT Syndication....